摘要
将运送H5亚型禽流感病毒DNA疫苗重组减毒鼠伤寒沙门氏菌以1.0×1010CFU剂量口服接种1日龄SPF雏鸡,结果表明重组菌对雏鸡具有良好的安全性。将重组菌SL7207(pVAX1-HA)和X4550(asd-pVAX1-HA)以2×109CFU的剂量两次口服免疫1日龄商品代伊莎褐蛋鸡,同时,将重组菌分别与pVAX1-IFN-γ或pVAX1-IL2(200μg/只)联合免疫,通过测定小肠粘膜抗体效价,结果显示,重组菌单独免疫组和联合免疫组能激发机体产生粘膜免疫应答,且与空载体组、空白对照组以及油苗组之间存在显著性差异(P<0.05)。攻毒后,免疫保护结果显示无论是重组菌单独免疫组还是联合免疫组均与空载体组和空白对照组之间存在显著性差异(P<0.05),而重组菌单独免疫组与联合免疫组之间不存在显著性差异,说明重组菌SL7207(pVAX1-HA)和X4550(asd-pVAX1-HA)能够提供机体抵抗HPAIV H5亚型强毒攻击的良好的免疫保护作用,这为进一步筛选出基于粘膜免疫途径的新型禽流感基因工程疫苗奠定了基础。
One-day-old SPF chickens were orally innoculated with recombinant attenuated Salmonella typhimurium SL7207（pVAX1-HA） at dosage of 10^10 CFU , and the results showed that the recombinant bacteria was safe to SPF chickens. One-day-old commercial ISA brown chickens were twice immunized orally with SL7207（pVAX1-HA） or X4550（pVAX1-HA） at dosage of 2 × 10^9 CFU, and with SL7207（pVAX1-HA） ＋ pVAX1-IFN-γ, SL7207 （pVAX1-HA） ＋ pVAXI-IL2, X4550 （pVAX1-HA） ＋ pVAXI-IFN-γ and X4550 （pVAX1-HA） ＋ pVAXI-IL2 at dosage of 2 × 10^9 CFU plus 200μg. It was shown that the intestinal mucosal antibody titers in immunized groups were significantly higher than that of chickens administrated with killed oilemulsified vaccine or that of negative control groups （P 〈 0.05） . The results of protective immunity showed both the recombinant bacteria immunized groups and groups immunized with recombinant bacteria plus recombinant plasmid pVAX1-IFN-γ or pVAXI-IL2 provided significant protection compared with that of the negative control groups （P〈 0.05）. These data suggest that the recombinant bacteria SL7207（pVAX1-HA） and X4550 （asd-pVAX1-HA） are useful in the development of the novel mucosal DNA vaccine against avian influenza.
出处
《病毒学报》
CAS
CSCD
北大核心
2006年第1期6-10,共5页
Chinese Journal of Virology
基金
国家"863"高技术项目(2002AA245051)
国家自然科学基金项目(30425031)
教育部资助项目(FANEDD200358
175)
关键词
减毒沙门氏菌
DNA疫苗
禽流感病毒
免疫效力
attenuated Salmonella typhimurium
DNA vaccine
avian influenza virus
immune efficacy
